L3VLUP
ProSign in

MRK · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

MRKLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • MRK
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterMRKLLY
Q3 202035 holders, $20.2bn33 holders, $14.1bn
Q4 202034 holders, $19.1bn29 holders, $17.3bn
Q1 202133 holders, $16.6bn24 holders, $23.0bn
Q2 202131 holders, $15.1bn24 holders, $27.8bn
Q3 202131 holders, $15.2bn31 holders, $29.9bn
Q4 202126 holders, $15.0bn31 holders, $34.7bn
Q1 202234 holders, $17.4bn24 holders, $35.3bn
Q2 202234 holders, $19.0bn33 holders, $42.7bn
Q3 202235 holders, $17.2bn31 holders, $43.4bn
Q4 202235 holders, $25.2bn31 holders, $46.6bn
Q1 202333 holders, $26.6bn33 holders, $44.3bn
Q2 202334 holders, $30.1bn37 holders, $59.6bn
Q3 202339 holders, $26.7bn44 holders, $67.6bn
Q4 202341 holders, $29.3bn45 holders, $73.6bn
Q1 202437 holders, $37.1bn41 holders, $95.3bn
Q2 202438 holders, $33.0bn43 holders, $110bn
Q3 202438 holders, $29.1bn45 holders, $107bn
Q4 202435 holders, $23.7bn46 holders, $93.9bn
Q1 202536 holders, $20.8bn42 holders, $98.4bn
Q2 202531 holders, $18.5bn43 holders, $93.2bn
Q3 202536 holders, $19.0bn39 holders, $86.7bn
Q4 202532 holders, $26.8bn41 holders, $123bn
Q1 202630 holders, $28.9bn39 holders, $106bn
Q2 202625 holders, $29.2bn44 holders, $132bn
MRK

Merck & Co Inc

Holders
35
Reported value
$23.7bn
Buyers
18
Sellers
19

Breadth -1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 49 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (32)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Quantbot Technologies LP, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, Two Sigma Investments LP, Voloridge Investment Management LLC, Wellington Management Group LLP, Woodline Partners LP

Only MRK (3)

Arrowstreet Capital LP, ExodusPoint Capital Management LP, Harris Associates LP

Only LLY (14)

Coatue Management LLC, Egerton Capital UK LLP, Freestone Grove Partners LP, Holocene Advisors LP, Jane Street Group LLC, Lone Pine Capital LLC, Marshall Wace LLP, Polen Capital Management LLC, Rokos Capital Management LLP, Soros Fund Management LLC, Susquehanna International Group LLP, Tiger Global Management LLC, Verition Fund Management LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →